AIML Innovations (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) has announced the appointment of Paul Dorian, MD, MSc, as its medical innovation architect (MIA) and head of the company’s medical advisory board, effective immediately.
Dr. Dorian succeeds Peter Kendall, who previously served as chair of the medical advisory board. Dr. Dorian has been working closely with AIML for several months, contributing to product strategy, clinical positioning, and innovation initiatives across the company’s MaxYield, CardioYield, and Insight360 platforms.
In a statement, Paul Duffy, executive chairman and CEO of AIML, commented, “Dr. Dorian’s appointment marks a pivotal milestone for AIML. He brings unparalleled expertise in cardiac electrophysiology, clinical research, and health-system innovation. As we expand into regulated clinical markets and large-scale deployments, his leadership will help ensure our technology meets the highest standards of clinical relevance, safety, and impact.”
